Breast Cancer 2026: ADCs, CDK4/6 Combinations, and the Endocrine Therapy Reset

The strategic landscape of hormone receptor-positive (HR+) metastatic breast cancer (mBC) has reached a definitive inflection point in 2026. The simultaneous arrival of Datopotamab deruxtecan (Dato-DXd) and the clinical setbacks of high-profile oral selective estrogen receptor degrader (SERD) trials, most notably the failure of the persevERA study, have fundamentally disrupted the long-standing treatment algorithm. For decades, the standard-of-care trajectory relied on a predictable five-year endocrine-based sequence; however, the emergence of the "ADC Cascade" has accelerated the transition to antibody-drug conjugate (ADC)-centric models much earlier in the patient journey.

This "Endocrine Therapy Reset" is necessitated by the staggering global burden of breast cancer, which remains the most frequent malignancy affecting women, accounting for 2.26 million new cases and 684,996 deaths annually. While endocrine therapy has long been the pillar of HR+ care, the failure of traditional sequencing to address emergent resistance has paved the way for ADCs to move into frontline and second-line settings. Three specific milestones define this era: the landmark DESTINY-Breast03 and DESTINY-Breast04 results which established Trastuzumab deruxtecan (T-DXd) in HER2-positive and HER2-low populations; the January 17, 2025, FDA approval of Datoway (Dato-DXd); and the late-stage failure of key oral SERDs to demonstrate superior outcomes in unselected populations. This shift represents a broader industry transition from a "protein-centric" classification system to a "pathway-centric" model of tumor identification.

The oncology market in 2026 is characterized by extreme commercial volatility. Efficacy is no longer the sole determinant of leadership; the "Total Cost of Care"—incorporating drug acquisition, complex administration, and the management of high-grade toxicities—now dictates formulary positioning.

Asset Label Scope Primary Commercial Barrier Payer Status Enhertu (T-DXd) HER2+ and HER2-low mBC High cost ($9,305/cycle) and ILD risk Preferred; US ICER is cost-effective Kadcyla (T-DM1) HER2+ mBC (Post-Trastuzumab) Relegated by T-DXd; lower efficacy profile Losing share; relegated to later lines Datoway (Dato-DXd) HR+/HER2-negative mBC Lack of OS significance; Stomatitis/Keratitis Emerging; positioned as ICC replacement

The Global Economic Divergence

A stark divergence exists between the U.S. and China regarding ADC adoption. In the United States, T-DXd is considered cost-effective with an Incremental Cost-Effectiveness Ratio (ICER) of $82,112/QALY, comfortably below the $150,000/QALY willingness-to-pay (WTP) threshold.

Conversely, in China, T-DXd presents an ICER of $305,041/QALY, nearly ten times the national WTP threshold of 37,653/QALY. For T-DXd to achieve significant market penetration in China, price reductions of 50–65% are required to reach a sustainable unit price of 12.06–$17.24/mg. Without such concessions, ADCs will remain "luxury" options outside the centralized procurement list.

Commercial Positioning of Datoway

Approved in January 2025, Datoway is being aggressively positioned by Daiichi Sankyo and AstraZeneca as a replacement for "Investigator's Choice" chemotherapy (eribulin, capecitabine, vinorelbine). By emphasizing a 37% reduction in the risk of progression compared to chemotherapy, the partners are attempting to capture the massive HR+ segment that has progressed on endocrine therapy but is not yet eligible for, or has already failed, HER2-directed ADCs.

In the 2026 landscape, cross-trial comparison has become the primary tactical tool for oncology strategy. Navigating the ADC market requires a rigorous evaluation of hazard ratios (HR) and p-values to determine where new assets sit within the evolving standard of care (SoC), specifically as ADCs begin to compete for the same patient populations in earlier lines of therapy.

Clinical Milestones and Asset Performance

• DESTINY-Breast03 (T-DXd): Head-to-head comparison against T-DM1 in HER2+ mBC.

* Data: 12-month PFS rate of 75.8% for T-DXd vs. 34.1% for T-DM1 (HR 0.28). * So What? Established T-DXd as the absolute second-line SoC, effectively displacing T-DM1 by nearly tripling the PFS rate.

• TROPION-Breast01 (Datoway): Comparison against Investigator’s Choice Chemotherapy (ICC) in HR+/HER2-low or negative mBC.

* Data: PFS 6.9 mo vs. 4.9 mo (HR 0.63, p <0.0001); OS 18.6 mo vs. 18.3 mo (not significant). * So What? Secured regulatory approval as a chemo-replacement, though the lack of OS benefit complicates its positioning against more established ADCs.

• ERADICATE (NCT07198724): Combination of Elacestrant (Orserdu) + Trastuzumab deruxtecan (T-DXd).

* Population: CDK4/6-resistant, HR+/HER2-low or HER2-ultralow mBC. * Endpoint: Safety/RP2D and Objective Response Rate (ORR). * So What? Targets the massive unmet need in ESR1-mutant populations, potentially creating a high-value "ADC + Endocrine" frontline combination.

• DESTINY-Breast04 (T-DXd): Comparison against ICC in HER2-low mBC.

* Data: Demonstrated significant improvements in both PFS and OS. * So What? Redefined the treatment of 50% of all breast cancer patients by validating "HER2-low" as a distinct, treatable clinical entity.

• DESTINY-Breast01 (T-DXd): Registrational single-arm study in heavily pretreated HER2+ mBC.

* Data: Median PFS of 16.4 months and ORR >60%. * So What? Provided the initial proof-of-concept for the high-potency DXd payload, setting the stage for the current ADC-dominant market.

• persevERA (Oral SERD): Giredestrant + Palbociclib vs. Letrozole + Palbociclib.

* Endpoint: Primary endpoint of PFS was not met. * So What? This failure accelerated the "Endocrine Reset," leaving a vacuum in the HR+ treatment sequence that Datoway and T-DXd are now filling.

• DESTINY-Breast11 (T-DXd): Phase 3 trial in the neoadjuvant setting for HER2+ early breast cancer.

* Population: High-risk HER2-positive early BC. * So What? Success here would move ADCs into the curative-intent setting, potentially replacing conventional neoadjuvant chemotherapy entirely.

• TROPION-Breast02 (Datoway): Phase 3 trial in previously untreated locally advanced/metastatic Triple-Negative Breast Cancer (TNBC).

* Endpoint: PFS and OS. * So What? Aims to expand the Datoway label into the high-growth TNBC segment as a frontline monotherapy.

• TROPION-Breast04 (Datoway): Combination of Datoway + Durvalumab.

* Population: PD-L1 unselected metastatic breast cancer. * So What? Testing the "ADC + IO" hypothesis to determine if TROP2-targeting can enhance immune-mediated cell death.

• DESTINY-Breast02 (T-DXd): T-DXd vs. Physician's Choice in HER2+ mBC patients previously treated with T-DM1.

* Data: Significant improvement in PFS and OS. * So What? Confirmed that T-DXd maintains potency even in patients who have failed prior-generation ADCs.

Analysis of the "OS Paradox"

The "OS Paradox" is best illustrated by the TROPION-Breast01 results, where a statistically significant and clinically meaningful PFS benefit (HR 0.63) failed to translate into an Overall Survival advantage (18.6 vs. 18.3 months). This disconnect complicates the prescribing logic, particularly in the HR+/HER2-low space. From a clinical perspective, this lack of OS divergence is widely attributed to the "crossover effect"; as patients in the control arm progressed, many received subsequent high-potency ADCs (like T-DXd) as later-line therapy, which "muddies" the survival data by extending the life of the control cohort.

Furthermore, this paradox highlights the difficulty of distinguishing between HER2-low and HER2-ultralow (defined as IHC 0 with any membranous staining). While Datoway targets TROP2 rather than HER2, its market share is directly challenged by the established survival benefit T-DXd demonstrated in the DESTINY-Breast04 population. Clinicians must now decide whether to prioritize the drug with the proven OS advantage (T-DXd) or the one positioned as a safer "chemo-replacement" (Datoway) earlier in the sequence.

From a strategic perspective, the OS Paradox presents a major hurdle for global market access. Payers, particularly in the European Union and the UK (NICE), historically view OS as the gold standard for reimbursement. In an era of high-cost therapeutics, a "PFS-only" benefit may be insufficient to justify premium pricing. Manufacturers of assets like Datoway may face restricted access or be forced to offer substantial discounts to offset the lack of definitive survival data, potentially limiting the commercial ceiling of these assets in more conservative regulatory environments.

The ADC Cascade requires a multi-stakeholder paradigm shift in risk assessment and value perception. Professionals must move beyond binary efficacy metrics to evaluate long-term patient management and health-system sustainability.

For Clinicians

The primary challenge is the shift in patient selection. The nuance between HER2-low and HER2-ultralow requires expert pathology coordination to avoid "under-treating" patients who could benefit from T-DXd. Furthermore, safety monitoring for ADCs is intensive. Clinicians must manage the DXd-platform's risk of Interstitial Lung Disease (ILD) while simultaneously monitoring for Datoway-specific signals such as high-grade stomatitis and keratitis (dry eye), which were significant in TROPION-Breast01.

For Commercial and Market Access

The WTP gap is the defining hurdle for the next 24 months. Biopharma teams in emerging markets must prepare for centralized drug procurement negotiations where "PFS-only" assets like Datoway may be deprioritized. Reaching the necessary cost-effectiveness thresholds in China (12.06–17.24/mg) will be critical for achieving the volume required to offset lower margins.

For Investors and Business Development

The elacestrant (Orserdu) + T-DXd combination (ERADICATE) is the primary valuation driver for late-stage HR+ pipelines. Following the failure of multiple oral SERDs as monotherapies, the industry is pivoting toward SERD+ADC combinations as a way to "rescue" the value of the SERD class. If ERADICATE proves successful in overcoming ESR1-mediated resistance, it will secure the frontline metastatic setting and create a high-value barrier to entry against competitor pipelines.

The "Endocrine Reset" is an active, ongoing evolution. The next 12 months will determine whether ADCs solidify their status as "frontline imperatives" or remain later-line alternatives.

Strategic Milestones

• Q1 2026: Final data readouts for TROPION-Breast02 and TROPION-Breast03, evaluating Datoway in TNBC and HR-low settings.
• Q2 2026: Anticipated regulatory updates for Datoway in the EU (CHMP) and China (NMPA) following Hong Kong pricing and access trends.
• Q2 2026: Primary completion of the ERADICATE dose-escalation phase, providing the first safety look at the SERD+ADC combo.
• Q3 2026: Mid-year analysis of TROPION-Breast04 and 05 assessing the impact of immunotherapy combinations.
• Q3 2026: Updated analysis of TROPION-Breast01 OS data to determine if longer follow-up provides more definitive survival clarity.
• Q4 2026: Results from DESTINY-Breast11, testing T-DXd in earlier neoadjuvant lines, which could fundamentally shift the curative-intent SoC.
• Q4 2026: Publication of detailed PRO (Patient Reported Outcomes) from the Datoway program to support "quality of life" value claims.
• Q4 2026: Initial clinical signals from next-generation ADCs targeting alternative pathways (e.g., Nectin-4) into the HR+ space.

Bullish vs. Bearish Scenario Analysis

• Bullish: Rapid ADC uptake in earlier lines driven by DESTINY-Breast11 success and the validation of SERD+ADC combos in ERADICATE, leading to a total replacement of conventional chemotherapy in HR+ disease.
• Bearish: Regulatory pushback on "PFS-only" approvals based on the TROPION-01 OS Paradox and continued cost-effectiveness failures in emerging markets limit global revenue and force massive price concessions.

As HER2-ultralow becomes the new frontline battleground, the biopharma professional's imperative is to remain agile as the "ADC Cascade" fundamentally resets the value of the endocrine backbone.

SOURCES

• Yang J, et al., 2022, Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer, Frontiers in Pharmacology. [https://doi.org/10.3389/fphar.2022.924126]
• FDA, 2025, FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer, FDA.gov.
• Daiichi Sankyo/AstraZeneca, 2024, Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial, Journal of Clinical Oncology.
• ClinicalTrials.gov, 2026, NCT07198724 (ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan), ClinicalTrials.gov.